Johnson & Johnson, Drugmaker | featured news

J&J AIDS drug shows promise

J&J AIDS drug shows promise

Two pivotal trials of a Johnson & Johnson experimental HIV drug found it worked as well as an existing drug, with fewer side effects but also with nearly twice as many patients failing to respond to treatment.

 

Johnson & Johnson buys 18 percent stake in Crucell

Health care giant Johnson & Johnson is jumping into the increasingly hot vaccine business by taking an 18 percent stake in Dutch biotechnology company Crucell NV and focusing more on preventive medicine....

 

J&J to Take Stake in Elan

J&J to Take Stake in Elan

J&J agreed to buy an 18.4% stake in Elan for $1 billion and acquire the rights to much of the Irish biotech company's research into drugs for Alzheimer's disease.

 

Subscribe to this RSS topic: Syndicate content